5 Common Mistakes That Can Slow Baby Development And What to Do Instead
It's easy to overthink baby development. With so many toys, classes, and milestone trackers out there, it can feel like you need to follow every program or get everything 'just right.' But babies don't need perfection to thrive. What they need is the opportunity to move, explore, connect, and feel safe.
That said, there are a few common habits that might unintentionally hold back their development. They're all fixable, and knowing what to tweak can help your baby grow with more confidence (and less pressure on you).
1. Relying too much on baby gear.
Swings, bouncers, and loungers have their place, especially when you need two hands. But when babies spend too much time in gear, it limits their opportunities to build essential muscle strength in their neck, shoulders, and core. Those muscles are key for rolling, crawling, and eventually walking.
What to try instead:
Aim for short, frequent bursts of tummy time throughout the day.
Start tummy time on your chest and or with a small rolled towel under your baby's chest if they're resistant at first.
Use a floor mirror to encourage them to lift their head and engage their core.
Try side-lying play as a bridge to rolling.
Keep baby gear short and balanced. No more than 20-30 minutes at a time.
2. Skipping floor time and free movement.
The floor is where development takes off. When babies have the space to move freely by reaching, scooting, and stretching, they're not just working on gross motor skills. They're building spatial awareness, coordination, and the ability to problem-solve through trial and error.
Ways to boost their floor play:
Place toys just out of reach to motivate rolling and reaching.
Create a safe 'yes space' with soft mats and minimal barriers.
Use high-contrast toys early on and gradually introduce textured items for sensory play.
3. Missing out on face-to-face interaction.
Your face is your baby's favorite thing to look at. These moments of eye contact, silly expressions, and back-and-forth sounds are powerful. They lay the foundation for language, emotional intelligence, and connection.
Simple ways to build in more connection:
Talk through your everyday routines like diaper changes, feedings, and walks outside.
Imitate your baby's coos and sounds to encourage back-and-forth communication.
Play peek-a-boo or simple interactive games.
Use exaggerated expressions. Babies love animated faces!
4. Focusing only on physical milestones.
It's easy to zero in on when your baby rolls, crawls, or sits up, but emotional development matters just as much. From the beginning, babies learn about trust, safety, and connection through how we respond to their cues. Every moment of comfort, eye contact, and gentle tone helps build a sense of emotional security.
Try these emotionally supportive strategies:
Babywearing and skin-to-skin contact for closeness and comfort.
Predictable routines that help your baby feel secure.
Reading books with emotional expressions and varied tones of voice.
Singing, humming, or simply talking to your baby. They're drawn to your voice.
Offering a calm, reassuring presence during fussier moments.
There's no one 'right' way to connect. What matters most is being responsive in a way that feels natural for both of you.
5. Using screens too early.
When you're home with a baby, screen time can be tempting. But for babies under one year, passive viewing doesn't offer the same developmental benefits as real-life interaction. It can also take time away from essential activities like movement, play, and connection.
Alternatives to screen time:
Play music and have a little dance party–babies love rhythm and movement.
Offer sensory bins or safe household items to explore different textures.
Read interactive books with flaps, mirrors, or bold images.
Let your baby watch you go about your day while narrating what you're doing.
Video chatting with loved ones is the exception; it's interactive and can help strengthen social bonds. The key is keeping screen time purposeful and limited in the early months.
What to dive deeper into screen time and how it affects development? Check out this PedsDocTalk YouTube video that explains more.
Final thoughts
You don't need to be perfect or follow a strict plan to support your baby's development. What matters most is being present, tuned in, and offering opportunities for connection and movement throughout the day.
By making a few small adjustments, like limiting baby gear, encouraging floor time, and reading books together, you're helping your baby build the foundation for lifelong skills. These small shifts add up.
Development in the first year isn't about hitting every milestone early; it's about creating an environment where your baby feels safe, supported, and ready to explore at their own pace.
Curious about which milestones to watch for in your baby's first year? Check out the free PedsDocTalk Milestones to Monitor guide. It offers a clear, supportive look at what to expect and when to check in with your child's pediatrician, without the pressure.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
The president vows to slash medication cost to an unachievable degree.
President Donald Trump has promised to reduce American drug prices by mathematically impossible figures of up to '1400 percent.' Speaking during a White House event attended by Republican members of Congress and his Cabinet, Trump said he would tackle the long-running issue of high medication costs in the U.S. But Trump did not set any achievable targets for that aim, instead outlining a range of percentages which would yield negative prices, meaning drug companies would have to pay people to take their medications.
Yahoo
2 minutes ago
- Yahoo
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates
HOUSTON, July 23, 2025--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the three months and six months ended June 30, 2025, on Wednesday, August 6, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, August 7, 2025. Conference Call Date: Thursday, August 7, 2025 Time: 10:30 am Eastern / 9:30 am Central Dial-In Number: (800) 343-4136 Primary or (203) 518-9843 Alternate Conference ID: USPHQ225 (In order to join this conference call,you will be required to provide the Conference ID listed above) To participate, please call in 15 minutes prior to start time. To listen to the live call, please go to and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 5, 2025 at USPH's website. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 768 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release. View source version on Contacts U.S. Physical Therapy, Hendrickson, Chief Financial OfficerEmail: Chendrickson@ Chris Reading, Chief Executive Officer(713) 297-7000 Three Part AdvisorsJoe Noyons(817) 778-8424